



# Supporting your research with our capabilities

BD Accuri™ C6 Plus Personal Flow Cytometer

BD FACSCelesta™ Cell Analyzer

BD LSRFortessa™ X-20 Cell Analyzer

BD FACSMelody™ Cell Sorter

One of the largest portfolios of reagents



**BD**

**Learn more >**

**Coffee and tea consumption and risk of prostate cancer in the European  
Prospective Investigation into Cancer and Nutrition**

Abhijit Sen<sup>1,2</sup>, Nikos Papadimitriou<sup>2</sup>, Pagona Lagiou<sup>3,4,5</sup>, Aurora Perez-Cornago<sup>6</sup>,  
Ruth C Travis<sup>6</sup>, Timothy J Key<sup>6</sup>, Neil Murphy<sup>7</sup> , Marc Gunter<sup>7</sup>, Heinz Freisling<sup>7</sup>,  
Ioanna Tzoulaki<sup>2,8</sup>, David C Muller<sup>8</sup>, Amanda J Cross<sup>8</sup>, David S Lopez<sup>9,10</sup>, Manuela  
Bergmann<sup>11</sup>, Heiner Boeing<sup>11</sup>, Christina Bamia<sup>3,12</sup>, Anastasia Kotanidou<sup>12,13</sup>, Anna  
Karakatsani<sup>12,14</sup>, Anne Tjønneland<sup>15</sup>, Cecilie Kyrø<sup>15</sup>, Malene Outzen<sup>15</sup>, María-Luisa  
Redondo<sup>16</sup>, Valerie Cayssials<sup>17</sup>, Maria-Dolores Chirlaque<sup>18-20</sup>, Aurelio  
Barricarte<sup>19,21,22</sup>, Maria-Jose Sánchez<sup>19,23</sup>, Nerea Larrañaga<sup>19,24</sup>, Rosario Tumino<sup>25</sup>,  
Sara Grioni<sup>26</sup>, Domenico Palli<sup>27</sup> , Saverio Caini<sup>27</sup>, Carlotta Sacerdote<sup>28</sup> , Bas Bueno-de-  
Mesquita<sup>8,29,30,31</sup>, Tilman Kühn<sup>32</sup>, Rudolf Kaaks<sup>32</sup> , Lena Maria Nilsson<sup>33</sup>, Rikard  
Landberg<sup>33,34</sup>, Peter Wallström<sup>35</sup>, Isabel Drake<sup>36</sup> , Bodil Hammer Bech<sup>38</sup>, Kim  
Overvad<sup>37</sup>, Dagfinn Aune<sup>8,38</sup>, Kay-Tee Khaw<sup>39</sup>, Elio Riboli<sup>8</sup>, Dimitrios  
Trichopoulos<sup>4,5,12</sup>, Antonia Trichopoulou<sup>3,12</sup>, Konstantinos K Tsilidis<sup>2,8</sup> 

**Authors' Affiliations**

<sup>1</sup>Department of Public Health and Nursing, Faculty of Medicine and Health Science,  
Trondheim, Norway

<sup>2</sup>Department of Hygiene and Epidemiology, University of Ioannina School of  
Medicine, Ioannina, Greece

<sup>3</sup>WHO Collaborating Center for Nutrition and Health, Department of Hygiene,  
Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian  
University of Athens, Athens, Greece

<sup>4</sup>Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/ijc.31634

<sup>5</sup>Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA

<sup>6</sup>Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

<sup>7</sup>International Agency for Research on Cancer, Lyon, France

<sup>8</sup>Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK

<sup>9</sup>Department of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas- School of Public Health, Houston, TX

<sup>10</sup>Division of Urology, The University of Texas Medical School, Houston, TX

<sup>11</sup>Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany

<sup>12</sup>Hellenic Health Foundation, Athens, Greece

<sup>13</sup>First Department of Critical Care Medicine and Pulmonary Services, University of Athens Medical School, Evangelismos Hospital, Athens, Greece.

<sup>14</sup>2nd Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Haidari, Greece

<sup>15</sup>Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark

<sup>16</sup>Public Health Directorate, Asturias, Spain

<sup>17</sup>Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

<sup>18</sup>Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain

<sup>19</sup>CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain

<sup>20</sup>Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain

<sup>21</sup>Navarra Public Health Institute, Pamplona, Spain

<sup>22</sup>Navarra Institute for Health Research (IdiSNA), Pamplona, Spain

<sup>23</sup>Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs. GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain

<sup>24</sup>Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Spain.

<sup>25</sup>Cancer Registry and Histopathology Unit, "Civic-M.P.Arezzo" Hospital, Ragusa, Italy

<sup>26</sup>Epidemiology and Prevention Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori *via Venezian 1*, 20133 Milano, Italy

<sup>27</sup>Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute—ISPO, Florence, Italy

<sup>28</sup>Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy

<sup>29</sup>Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, The Netherlands

<sup>30</sup>Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands.

<sup>31</sup>Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Pantai Valley, 50603, Kuala Lumpur, Malaysia.

<sup>32</sup>Division of Cancer Epidemiology, German Cancer Research Center (DKFZ)

<sup>33</sup>Public health and clinical medicine, Nutritional research Umeå University

<sup>34</sup>Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden

<sup>35</sup>Nutrition Epidemiology Research Group. Dept. of Clinical Sciences, Lund University, Malmö, Sweden

<sup>36</sup>Department of Clinical Sciences in Malmö, Lund University, Sweden

<sup>37</sup>Department of Public Health, Section for Epidemiology, Aarhus University, Denmark

<sup>38</sup>Björknes University College, Oslo, Norway

<sup>39</sup>University of Cambridge, School of Clinical Medicine, Cambridge, United Kingdom.

† Deceased

**Running title:** Coffee and tea consumption and prostate cancer risk in EPIC

**Correspondence to:** Konstantinos K Tsilidis, PhD, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK. Phone: +44 (0) 2075942623. E-mail: [k.tsilidis@imperial.ac.uk](mailto:k.tsilidis@imperial.ac.uk)

For information on how to submit an application for gaining access to EPIC data and/or biospecimens, please follow the instructions at

<http://epic.iarc.fr/access/index.php>

**Key words** Coffee, tea, decaffeinated, caffeinated, prostate cancer, EPIC

**Abbreviations**

BMI Body Mass Index

CI Confidence Interval

EPIC European Prospective Investigation into Cancer and Nutrition

HR Hazard Ratio

RR Relative Risk

TNM Tumor Node-metastasis

WCRF World Cancer Research Fund

**Article category** Cancer Epidemiology

**Novelty and impact**

Numerous studies have assessed the association of coffee and tea consumption with risk of total prostate cancer and results are inconsistent. Total prostate cancer mainly reflects propensity to have a biopsy; hence, more attention must be given to advanced and fatal disease. Few cohort studies have so far examined these associations according to disease stage, grade or fatality. Our findings from this large prospective cohort study does not support any association between drinking tea or coffee, with or without caffeine, and risk of total prostate cancer or cancer by stage, grade or fatality.

**ABSTRACT**

The epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow-up. Data on coffee and tea consumption were collected through validated country-specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 mL/day and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 mL/day versus 12 mL/day) the HRs were 1.02 (95% CI, 0.94-1.09) and 0.98 (95% CI, 0.90-1.07) for risk of total prostate cancer, and 0.97 (95% CI, 0.79-1.21) and 0.89 (95% CI, 0.70-1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.



## INTRODUCTION

Prostate cancer is the most frequently diagnosed cancer amongst men in developed nations, and the age-standardized incidence rate of prostate cancer has been generally increasing worldwide<sup>1-3</sup>. This increase in incidence was presumably due to the introduction of prostate specific-antigen screening<sup>3</sup>. The etiology of this malignancy remains largely unclear, as only old age, black race, positive family history, prostate cancer susceptibility polymorphisms and possibly height and high circulating insulin-like growth factor I concentrations are established risk factors<sup>4-7</sup>. No dietary risk factors for prostate cancer have been firmly established<sup>7,8</sup>.

Tea and coffee are the two most widely consumed beverages in the world. In-vitro and animal studies have suggested that anti-oxidative and anti-inflammatory properties of polyphenols present in coffee and tea, such as catechins and diterpenes, might reduce the risk of prostate cancer<sup>9-11</sup>.

The association between coffee, tea and risk of total prostate cancer risk has been widely investigated in epidemiological studies, but the findings are inconsistent<sup>8,12-15</sup>. Most cohort studies have reported null associations, but many studies were limited by relatively small sample sizes, short follow-up time, lack of detailed adjustment for potential confounders, lack of information on coffee types and preparations, and scarce cancer stage and grade information. Hence, in the present large prospective study, we aimed to examine the association of coffee (total, caffeinated, decaffeinated) and tea intake with risk of total prostate cancer or risk by stage, grade and fatality in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.

## MATERIAL AND METHODS

### *Study Design*

EPIC is an ongoing multicenter prospective cohort study designed to investigate risk factors of cancer and other chronic diseases. There are 23 EPIC centers in 10 European countries (i.e. Denmark, France, Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden, and United Kingdom [UK]) that recruited more than half a million participants in the 1990s. Details about the cohort population and the data collection procedures have been described elsewhere <sup>16</sup>.

In the present study, participants from France and Norway, Naples (Italy) and Utrecht (The Netherlands) were excluded because these centers included only women. Data from 142,196 male participants were included for analysis after excluding 3,972 men with prevalent cancers (other than non-melanoma skin cancer) at recruitment, and 5,766 men with incomplete dietary or non-dietary information or men with an extreme energy intake relative to estimated energy requirement. All subjects gave written informed consent and the Institutional Review Boards of the International Agency for Research on Cancer and of all EPIC recruitment centers approved the study.

### *Exposure Assessment*

Dietary assessment over the 12 months before recruitment was recorded using validated country-specific food questionnaires including a range of 88 to 266 food items. Questionnaires were usually self-administered, except in Greece, Spain and Ragusa in Italy, where trained interviewers were used. Data on caffeinated and decaffeinated coffee were not available in the EPIC centers of Ragusa (Italy), Umeå (Sweden) and Denmark, whereas data on decaffeinated coffee was not available in

Malmö (Sweden). Further details on the diet questionnaires and their validation are described elsewhere<sup>16,17</sup>. The recorded number of cups of coffee and tea consumed per day, week, or month were converted to millilitres per day (ml/day). This conversion was completed by each center as the cup sizes varied between countries. As coffee and tea intake differed substantially by country, country-specific fourths or thirds for these beverages were used based on the distribution of intake among controls after excluding the non-consumers at recruitment.

### *Assessment of Prostate Cancer*

A total of 7,036 men were diagnosed with first incident prostate cancer according to the International Classification of Diseases 10th revision code. Follow-up began from the date of recruitment and ended at either the date of diagnosis of prostate cancer, date of death due to any reason or last known contact, or end of follow-up through 2015, whichever came first. Incident prostate cancer diagnoses were based on population-based cancer registries in Denmark, Italy, The Netherlands, Spain, Sweden, and the UK. An active follow-up including direct or next of kin communication and/or combination of different sources of ascertainment including health insurance records, regional health departments, municipality registries, hospital records and pathology registries were used in Germany and Greece. Of the 7,036 incident prostate cancer cases, 4,030 (57%) had stage information and 4,483 cases (64%) had grade information. Tumours were classified as localized (tumor-node-metastasis [TNM] staging score of T0-T2 and N0/Nx and M0, or stage coded in the recruitment center as localized; n= 2,641) or advanced prostate cancer (T3-T4 and/or N1-N3 and/or M1, or stage coded in the recruitment center as metastatic; n= 1,389). Further, tumours were classified as low-intermediate grade (Gleason score of <8, or

grade coded as well, moderately, or poorly differentiated; n=3,757) or high-grade prostate cancer (Gleason score of  $\geq 8$ , or grade coded as undifferentiated; n=726).

During the follow-up period, 936 fatal cases of prostate cancer were identified.

### Statistical Analysis

Hazard ratios (HR) and 95% confidence intervals (CIs) were computed for the associations between coffee and tea intake and risk for prostate cancer using Cox proportional hazards regression models with age as the underlying time-scale. The models were stratified for age at recruitment in 5-year intervals (<50, 50-54, 55-59, 60-64, 65-69,  $\geq 70$  years) and EPIC-participating center to control for differences in recruitment or follow-up procedures and questionnaires format. The proportionality of hazards was verified based on the slope of the Schoenfeld residuals over time, and no evidence of violation was detected.

The multivariable models were adjusted for a set of *a priori*-determined covariates that included smoking status (never, former, current or missing), education (up to high school, university graduate, or missing), body mass index (BMI in fifths: <23.6,  $\geq 23.6$  to < 25.5,  $\geq 25.5$  to < 27.2,  $\geq 27.2$  to < 29.4,  $\geq 29.4$  kg/m<sup>2</sup>, or missing), physical activity index<sup>18</sup> (inactive, moderate inactive, moderate active, active, or missing), history of diabetes (no, yes, missing), alcohol (non-consumers, <5, 5-14.9, 15-29.9, or >30 g/day), and intake of total energy (continuous in kcal/day), fish (continuous, g/day), calcium (continuous, mg/day), and fruits and vegetables (continuous, g/day). Coffee and tea intake were further mutually adjusted for each other in respective models. Similarly, caffeinated coffee and decaffeinated coffee were mutually adjusted. Missing values were assigned to separate categories for

smoking status (1.4%), education (2.7%), physical activity (2.2%), and diabetes (9.4%).

The consumption of coffee and tea was modeled with both categorical (country-specific fourths or thirds) and continuous terms (per 200 mL for coffee or 100 mL for caffeinated coffee and tea or 50 mL for decaffeinated coffee, depending on the range of intake of each beverage type). Non-consumers were defined as participants who did not consume the beverage under evaluation at recruitment, but could consume other beverages. For categorical analyses, the low consumers were used as the reference category. In separate analyses, we included a quadratic term for coffee or tea consumption to assess potential nonlinear associations.

We also assessed potential interactions on the multiplicative scale by age at enrollment (<60 vs.  $\geq 60$  years), smoking status (never vs. ever smokers), BMI (<25, 25-29.9,  $\geq 30$  Kg/m<sup>2</sup>) and physical activity (inactive and moderately inactive vs. moderately active and active). Multiplicative interaction terms were incorporated to the models and likelihood-ratio tests were used to test for interaction. Country-specific analyses were also performed. Heterogeneity of associations across countries and by stage and grade of prostate cancer was explored using the Cochran's Q test and the I<sup>2</sup> metric of inconsistency.

A range of sensitivity analyses were also performed by (i) excluding men diagnosed with prostate cancer in the first two years of follow-up to limit the likelihood that the observed associations were due to change of coffee or tea consumption produced by extant cancers, (ii) performing further adjustments for employment, height, waist circumference, hip circumference, waist-to-hip ratio, red and processed meat consumption and a more detailed variable for smoking status (never, former quit  $\leq 10$  years ago, former quit 11-20 years ago, former quit >20 years

ago, current with 1-15 cigarettes/day, current with 16-25 cigarettes/day, current with >25 cigarettes/day, current with pipe/cigar or occasional use), or (iii) considering non-consumers as the reference group. When Gleason score cut-point of 7 (instead of 8) was used to define prostate cancer grade or when T3a tumours were not considered as advanced cases in additional sensitivity analyses, the associations of coffee and tea intake in relation to prostate cancer were very similar (data not shown).

All P-values were two-sided and statistical analyses were conducted using STATA version 14 (Stata Corp, college Station, TX).

## RESULTS

**Supplemental Table 1** describes the baseline distribution of exposure and outcome information by country in EPIC. A total of 7,036 men were diagnosed with prostate cancer after a mean 14 years of follow-up. The mean age at enrolment in the cohort was 52 years. Of the 142,196 study participants, 95% drank coffee, 64% drank tea, 53% drank caffeinated coffee and 23% drank decaffeinated coffee. The highest median consumption of coffee was reported in Denmark (900 ml/day) and the lowest in Italy (91 ml/day). For caffeinated coffee, the highest and lowest median intakes were reported in the Netherlands (542 ml/day) and Spain (2 ml/day), respectively. The highest and lowest median intakes of decaffeinated coffee were reported in The Netherlands (75 ml/day) and Greece (0.5 ml/day), respectively. The highest median consumption of tea was observed in the UK (475 ml/day) and the lowest in Greece (0.5 ml/day).

The age and country-adjusted baseline characteristics of the men by categories of coffee and tea intake are presented in **Table 1**. Participants consuming higher volumes of coffee were slightly younger, more likely to have a paid employment,

more often current smokers, less physically active, reported more total energy intake and consumed more red and processed meat, but less fish, fruits and vegetables.

Participants in the highest tertile of tea consumption were more likely to be educated, less likely to smoke and to have diabetes, reported a lower total energy intake and consumed less alcohol, red and processed meat, fish, fruits and vegetables.

In multivariable Cox models, we observed no association between total coffee intake and risk of total prostate cancer comparing highest to lowest consumers (HR, 1.02; 95% CI, 0.94-1.09) (**Table 2**). The HR associated with a linear increase in coffee consumption per 200 ml/day was 1.00 (95% CI, 0.98 -1.01). Similarly, we observed no association between tea intake and total prostate cancer risk (highest vs. lowest consumers: HR, 0.98; 95% CI, 0.90 – 1.07) (**Table 3**). Consumption of caffeinated or decaffeinated coffee was also not associated with total prostate cancer risk (**Tables 4 and 5**). Non-consumers of coffee and tea were at a similar risk for total prostate cancer risk compared with consumers in the lowest category of coffee and tea consumption. Moreover, we found no associations of coffee and tea consumption for subtypes of prostate cancer risk defined according to stage, grade or fatality (**Table 2-5**). There was no evidence of heterogeneity for associations by stage and grade of prostate cancer (all P-values > 0.10). No evidence was observed for any non-linear association (data not shown).

We also found no clear evidence for any multiplicative interaction by age at recruitment, smoking status, obesity and physical activity (**Table 6**). When analyses were performed by EPIC-participating country, all associations were null and there was no between-country heterogeneity (**Table 6**). In sensitivity analyses, when 279 prostate cancer cases diagnosed within the first 2 years of follow-up were excluded, or after additional adjustment for a more detailed list of potential confounders, or after

considering non-consumers as the reference group, all results were very similar (data not shown).

## DISCUSSION

In this large prospective multi-center cohort study of 142,196 men, of whom 7,036 were diagnosed with prostate cancer during 14 years of follow-up, we found no evidence of an association between coffee or tea consumption and risk of total prostate cancer. Likewise, null associations were observed for caffeinated and decaffeinated coffee consumption and for associations by prostate cancer grade, stage, fatality, or according to age, BMI, smoking status and physical activity.

Findings from previous studies on total coffee consumption and risk of total prostate cancer have been inconsistent with most, though not all studies, reporting null results<sup>8,12-15,19</sup>. The meta-analysis of eight cohort studies conducted by the World Cancer Research Fund (WCRF) Continuous Update Project (CUP) in 2014 revealed a summary relative risk (RR) of 0.99 (95% CI, 0.98-1.00) per 1 cup/day<sup>7</sup>, which was in agreement with findings in the current study. Critical appraisals of the literature have categorized the association between coffee and prostate cancer risk under limited or weak evidence<sup>8,19</sup>. Other more recent and slightly larger meta-analyses reported either similar null findings (13 cohorts; RR, 0.98; 95% CI, 0.96-1.00) or weak inverse results (14 cohorts; RR, 0.97; 95% CI, 0.96-0.98) per 2 cups of total coffee per day<sup>13,14</sup>. A recently published Mendelian randomization study observed no association between genetically predicted coffee consumption and prostate cancer incidence or progression<sup>20</sup>.

Prostate cancer is a heterogeneous disease and conducting investigations by stage, grade or fatality are important for identifying associations specific for fatal



tumours or tumours that are likely to advance to metastatic disease. Unfortunately, less than half of the available cohort studies have investigated such associations <sup>7, 21-</sup>  
<sup>24</sup> Total coffee consumption (per 1 cup/day) was not associated with risk of fatal prostate cancer in the WCRF-CUP meta-analysis (4 cohorts; RR, 0.97; 95% CI, 0.93-1.00) <sup>7</sup> or in another meta-analysis (4 cohorts; RR, 0.76; 95% CI, 0.55-1.06) that compared highest to lowest consumption <sup>13</sup>, and a similar result was observed for advanced prostate cancer (6 cohorts; RR, 0.82; 95% CI, 0.61-1.10) <sup>13</sup>. In agreement with the meta-analyses and most other published studies <sup>21, 25, 26</sup>, the current study also found no association between total coffee consumption with prostate cancer by stage, grade or fatality. A strikingly different result was observed in the Health Professionals Follow-up Study (HPFS), which found a 60% lower risk of lethal prostate cancer among men who drank six or more cups of coffee per day compared to nondrinkers (RR, 0.40; 95% CI, 0.22-0.75) <sup>22</sup>.

Study differences may explain the discrepancy between our findings and those in HPFS. In EPIC, we had a narrower range of coffee intakes (inter-quartile range, 139-665 mL/d) compared to HPFS, but other North American or European studies with similar ranges of coffee consumption to HPFS observed null findings for coffee and fatal prostate cancer <sup>7, 21</sup>. When we performed an analysis in EPIC between the 5,018 men, 46 of which develop fatal prostate cancer, who drank six or more cups (approximately 1,418 ml) of coffee per day compared to nondrinkers, the results were null (HR, 1.04; 95% CI, 0.67-1.62). Evidence from experimental studies appears to suggest that coffee and tea, which are major sources of antioxidants, may have an inhibitory effect on carcinogenesis of prostate cancer <sup>10, 27, 28</sup>, which could be explained by the fact that very high doses of coffee or tea are used in the laboratory studies but it is also plausible that there is no effect in humans. A total of 642 fatal

cases were included in HPFS, of which only 12 cases drank six or more cups/day; therefore, a future analysis with larger follow-up from HPFS may assist in obtaining a more stable estimate for the top consumption category.

On the contrary, the HPFS has time-updated information on coffee consumption every 4 years, whereas many of the other cohorts, including EPIC, rely only on baseline assessments and are unable to account for dietary changes during follow-up. Such changes could lead to non-differential measurement error in the assessment of coffee consumption, which could bias results towards the null.

Diverging findings in different studies might be also owing to the different types of raw coffee and the different concentrations and preparations, as the particle content and dissolved caffeine content may differ<sup>29-33</sup>. We did not identify a differing association by caffeinated or decaffeinated coffee consumption, similar to HPFS and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening study cohort<sup>22, 30</sup>, but these and other types of coffee (e.g., type of coffee bean, roasting and brewing methods) should be investigated in greater detail in future studies.

Previous studies investigating the association between tea consumption and risk of prostate cancer have largely produced null results<sup>7, 12, 15</sup>. A recent meta-analysis of 28 cohort and case-control studies reported null relative risks of 0.86 (95% CI, 0.69-1.04), 0.88 (95% CI, 0.73-1.02) and 0.79 (95% CI, 0.43-1.14) comparing highest to lowest consumption of total, black or green tea, respectively<sup>12</sup>. The summary finding in the 9 included cohort studies for total tea intake was also null (RR, 0.98; 95% CI, 0.86-1.09), in agreement with the findings in the current study.

The present study has a number of strengths, including its prospective design that minimizes reverse causation to a large extent, the large number of prostate cancer cases ascertained over a long follow-up period, information on stage, grade and

fatality of prostate cancer, data on caffeinated and decaffeinated coffee as well as rich data on a wide-range of potential confounders. Nonetheless, the study also has some limitations. First, information on coffee and tea intake was self-reported only at recruitment, which will inevitably be imperfect. However, this information in EPIC was shown to be reliable and valid compared to repeat food frequency questionnaires and multiple 24-hour diet recalls<sup>17</sup>. Second, we did not collect information about temperature and type of tea consumption (green, black or other types), although Europeans habitually drink black tea at warm temperature. The potential addition of milk to the tea was also not captured in the questionnaires. Third, the serving size and concentration of coffee and tea consumed are different among countries included in this study, but our results used country-specific cut-off points that may minimize misclassification.

In conclusion, our findings suggest no evidence of association between coffee or tea consumption and risk of prostate cancer. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages.

**Conflict of interest:** The authors declare no conflict of interest

**Financial Support:** This study was supported by the World Cancer Research Fund International Regular Grant Programme (WCRF 2014/1180 to KKT). First author, AS has received Grants from Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology. The funding sources had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the article for publication. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) PI13/00061 (EPIC-Granada) and, PI13/01162 (EPIC-Murcia), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII Health Research Funds RD12/0036/0018 (cofounded by FEDER funds/European Regional Development Fund ERDF) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 for EPIC-

Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK).

Accepted Article

## REFERENCES

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. *European urology* 2012;61:1079-92.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *European journal of cancer* 2013;49:1374-403.
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136:E359-86.
4. Travis RC, Appleby PN, Martin RM, Holly JMP, Albanes D, Black A, Bueno-de-Mesquita HBA, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, et al. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. *Cancer Res* 2016;76:2288-300.
5. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, et al. Prevention and early detection of prostate cancer. *Lancet Oncol* 2014;15:e484-92.
6. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. *Br J Cancer* 1997;76:1115-8.
7. Discacciati A, Orsini N, Andersson SO, Andren O, Johansson JE, Mantzoros CS, Wolk A. Coffee consumption and risk of localized, advanced and fatal prostate cancer: a population-based prospective study. *Ann Oncol* 2013;24:1912-8.
8. Markozannes G, Tzoulaki I, Karli D, Evangelou E, Ntzani E, Gunter MJ, Norat T, Ioannidis JP, Tsilidis KK. Diet, body size, physical activity and risk of prostate cancer: An umbrella review of the evidence. *Eur J Cancer* 2016;69:61-69.
9. Huber WW, Rossmannith W, Grusch M, Haslinger E, Prustomersky S, Peter-Vorosmarty B, Parzefall W, Scharf G, Schulte-Hermann R. Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. *Food Chem Toxicol* 2008;46:1230-8.
10. Huber WW, Teitel CH, Coles BF, King RS, Wiese FW, Kaderlik KR, Casciano DA, Shaddock JG, Mulder GJ, Ilett KF, Kadlubar FF. Potential chemoprotective effects of the coffee components kahweol and cafestol palmitates via modification of hepatic N-acetyltransferase and glutathione S-transferase activities. *Environ Mol Mutagen* 2004;44:265-76.
11. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: antioxidants and beyond. *Am J Clin Nutr* 2005;81:215S-17S.
12. Lin YW, Hu ZH, Wang X, Mao QQ, Qin J, Zheng XY, Xie LP. Tea consumption and prostate cancer: an updated meta-analysis. *World journal of surgical oncology* 2014;12:38.

13. Liu H, Hu GH, Wang XC, Huang TB, Xu L, Lai P, Guo ZF, Xu YF. Coffee consumption and prostate cancer risk: a meta-analysis of cohort studies. *Nutrition and cancer* 2015;67:392-400.
14. Wang A, Wang S, Zhu C, Huang H, Wu L, Wan X, Yang X, Zhang H, Miao R, He L, Sang X, Zhao H. Coffee and cancer risk: A meta-analysis of prospective observational studies. *Scientific reports* 2016;6:33711.
15. Zhang YF, Xu Q, Lu J, Wang P, Zhang HW, Zhou L, Ma XQ, Zhou YH. Tea consumption and the incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation* 2015;24:353-62.
16. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjønneland A, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* 2002;5:1113-24.
17. Kaaks R, Slimani N, Riboli E. Pilot phase studies on the accuracy of dietary intake measurements in the EPIC project: overall evaluation of results. *European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol* 1997;26 Suppl 1:S26-36.
18. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, Day NE. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Public Health Nutr* 2003;6:407-13.
19. World, Cancer, Research, Fund, International/, American, et al. Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer. 2014.
20. Taylor AE, Martin RM, Geybels MS, Stanford JL, Shui I, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, et al. Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. *Int J Cancer* 2017;140:322-28.
21. Bosire C, Stampfer MJ, Subar AF, Wilson KM, Park Y, Sinha R. Coffee consumption and the risk of overall and fatal prostate cancer in the NIH-AARP Diet and Health Study. *Cancer Causes Control* 2013;24:1527-34.
22. Wilson KM, Kasperzyk JL, Rider JR, Kenfield S, van Dam RM, Stampfer MJ, Giovannucci E, Mucci LA. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. *Journal of the National Cancer Institute* 2011;103:876-84.
23. Hsing AW, McLaughlin JK, Schuman LM, Bjelke E, Gridley G, Wacholder S, Chien HT, Blot WJ. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. *Cancer research* 1990;50:6836-40.
24. Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS. Coffee consumption and prostate cancer risk: further evidence for inverse relationship. *Nutrition journal* 2012;11:42.

25. Arab L, Su LJ, Steck SE, Ang A, Fontham ET, Bensen JT, Mohler JL. Coffee consumption and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. *Nutr Cancer* 2012;64:637-42.
26. Nomura A, Heilbrun LK, Stemmermann GN. Prospective study of coffee consumption and the risk of cancer. *J Natl Cancer Inst* 1986;76:587-90.
27. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. *Proc Natl Acad Sci U S A* 2001;98:10350-5.
28. Cardenas C, Quesada AR, Medina MA. Anti-angiogenic and anti-inflammatory properties of kahweol, a coffee diterpene. *PLoS One* 2011;6:e23407.
29. Tverdal A. Boiled coffee consumption and the risk of prostate cancer: follow-up of 224,234 Norwegian men 20-69 years. *British journal of cancer* 2015;112:576-9.
30. Hashibe M, Galeone C, Buys SS, Gren L, Boffetta P, Zhang ZF, La Vecchia C. Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort. *British journal of cancer* 2015;113:809-16.
31. Farah A, de Paulis T, Trugo LC, Martin PR. Effect of roasting on the formation of chlorogenic acid lactones in coffee. *Journal of agricultural and food chemistry* 2005;53:1505-13.
32. Niseteo T, Komes D, Belscak-Cvitanovic A, Horzic D, Budec M. Bioactive composition and antioxidant potential of different commonly consumed coffee brews affected by their preparation technique and milk addition. *Food chemistry* 2012;134:1870-7.
33. Stavric B, Klassen R, Watkinson B, Karpinski K, Stapley R, Fried P. Variability in caffeine consumption from coffee and tea: possible significance for epidemiological studies. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association* 1988;26:111-8.



**Table 1 Country and age-adjusted characteristics at recruitment by coffee or tea intake in EPIC<sup>1</sup>**

Characteristics	Fourths of Frequency of observed total coffee consumption (ml/day)				
	Non-consumers	1 (Low)	2 (Moderately low)	3 (Moderately high)	4 (High)
Mean age (SD) , year	53.1 (SD=10.7)	52.7 (SD=10.7)	53.0 (SD=9.6)	50.5 (SD=9.9)	49.7 (SD=9.5)
University graduate (95% CI),%	23.7 (22.7 – 24.8)	27.7 (27.3 – 28.2)	26.3 (25.8 – 26.8)	27.5 (27.0 – 28.0)	25.9 (25.4 – 26.5)
Current Smoker (95% CI) , %	18.6 (17.7 – 19.6)	21.8 (21.4 – 22.3)	26.0 (25.6 – 26.5)	33.5 (33.0 – 34.0)	43.1 (42.5 – 43.6)
Employed (95% CI) , %	75.6 (74.3 – 76.8)	78.9 (78.4 – 79.3)	81.0 (80.6 – 81.6)	81 (81 – 82)	83 (83 – 84)
Physically active (95% CI) , %	50.4 (49.2 – 51.6)	50.8 (50.3 – 51.3)	50.8 (50.2 – 51.3)	48.6 (48.0 – 49.1)	23 (22 – 23)
Mean body mass index (95% CI) , %	26.7 (26.6 – 26.8)	26.5 (26.5 – 26.6)	26.5 (26.4 – 26.5)	26.7(26.6 – 26.7)	26.8 (26.7 – 26.8)
Diabetes (95% CI),%	36.1 (32.1 – 40.6)	29.8 (28.2– 31.5)	30.1 (28.4 – 32.0)	26.4 (24.7 – 28.2)	35.9 (33.8 – 38.2)
Daily mean (95% CI) dietary intake					
Energy, kcal	2355 (2340 – 2371)	2343 (2336 – 2349)	2368 (2362 – 2375)	2448 (2441 – 2456)	2524 (2517 – 2532)
Alcohol, g	17.4 (16.9 – 18.0)	21.6 (21.4 – 21.8)	20.9 (20.7 – 21.1)	20.9 (20.6 – 21.1)	20.2 (19.9 – 20.4)
Fruits and vegetables, g	435.1 (429.2 – 441.0)	435.4 (432.9 – 438.0)	376.3 (373.7 – 379.0)	395.9 (393.0 – 398.7)	378.9 (375.9 – 381.8)
Red and processed meat, g	54.1 (53.2 – 55.0)	55.5 (55.1 – 55.9)	55.6 (55.2 – 56.0)	54.4 (54.0 – 54.9)	56.1 (55.6 – 56.5)
Fish, g	33.3 (32.7 – 34.0)	28.2 (27.9 – 28.5)	28.0 (27.7 – 28.3)	25.7 (25.4 – 26.0)	26.5 (26.2 – 26.9)
Calcium, mg	1050 (1042 – 1058)	1044 (1041– 1048)	1041 (1037 – 1044)	1033 (1029 – 1037)	1052 (1048 - 1056)

  

Characteristics	Thirds of Frequency of observed tea consumption (ml/day)			
	Non-consumers	1 (Low)	2 (Moderate)	3 (High)
Mean age (SD), year	53.5 (SD=8.7)	50.1 (SD=11.4)	51.3 (SD=10.2)	50.9 (SD=10.2)
University graduate (95% CI),%	18.4 (18.0 – 18.7)	31.0 (30.5 – 31.5)	30.4 (29.9 – 30.9)	34.2 (33.5 – 34.8)
Current Smoker (95% CI) , %	38.4 (37.9 – 38.8)	27.0 (26.5 – 27.4)	24.6 (24.1 – 25.1)	21.7 (21.1 – 22.3)
Employed (95% CI),%	79.5 (79.1 – 79.9)	80.8 (80.3 – 81.2)	82.2 (81.7 – 82.6)	81.1 (80.6 – 81.7)
Physically active (95% CI) , %	48.9 (48.5 – 49.4)	48.0 (47.5 – 48.5)	52.0 (51.5 – 52.6)	49.6 (48.9 – 52.6)
Mean body mass index (95% CI) , %	27.1 (27.1 – 27.2)	26.2 (26.1 – 26.3)	26.2 (26.1 – 26.3)	25.9 (25.8 – 25.9)
Diabetes (95% CI),%	34.5 (32.9 – 36.1)	27.2 (25.5 – 29.0)	28.5 (26.7 – 30.4)	18.8 (27.5 – 32.1)
Daily mean (95% CI) dietary intake <sup>1</sup>				
Energy, kcal	2500 (2494 – 2506)	2278 (2272 – 2285)	2426 (2419 – 2433)	2412 (2403 – 2420)
Alcohol, g	23.4 (23.2 – 23.6)	20.3 (20.1 – 20.5)	19.7 (19.4 – 19.9)	17.4 (17.1 – 17.7)
Fruits and vegetables, g	416 (414 – 418)	410 (408 – 413)	384 (381 – 387)	369 (365 – 372)

Red and processed meat, g	58.9 (58.5 – 59.2)	52.3 (51.9 – 52.7)	58.0 (57.5 – 58.4)	48.7 (48.2 – 49.2)
Fish, g	34.0 (33.7 – 34.2)	23.4 (23.1 – 23.7)	26.2 (25.9 – 26.5)	21.8 (21.5 – 22.2)
Calcium, mg	985 (982 – 988)	1075 (1071 – 1078)	1075 (1071 – 1078)	1075 (1070 – 1079)

**Abbreviations:** EPIC, European Prospective Investigation into Cancer and Nutrition, CI, confidence interval, SD, Standard deviation

<sup>1</sup> Age at recruitment-adjusted means and proportions are presented using linear and logistic regression models, respectively. The means of dietary intake are also adjusted for daily energy intake and EPIC center.

**Table 2 Hazard ratio (HR) and 95% confidence interval (CI) for the association between total coffee intake and risk of total prostate cancer and cancer by stage, grade and fatality**

Characteristics	Fourths of observed total coffee intake <sup>1</sup>					Per 200 ml N= 135,035
	Non-consumer N= 7,161	1 (Low) N= 39,007	2 (Moderately low) N= 35,691	3 (Moderately High) N= 30,690	4 (High) N= 29,647	
<i>Median coffee intake (ml /day)</i>	0	103	376	500	855	
<b>All prostate cancer (No. of cases)</b>	369	1,996	1,962	1,438	1,271	6,667
Crude HR (95% CI) <sup>2</sup>	1.07 (0.96 – 1.20)	1.00 (ref)	1.02 (0.96 – 1.09)	0.99 (0.93 – 1.07)	0.99 (0.82 – 1.05)	0.99 (0.98 – 1.01)
Multivariable adjusted HR (95% CI) <sup>3</sup>	1.07 (0.95 – 1.19)	1.00 (ref)	1.03 (0.97 – 1.10)	1.02 (0.95 – 1.09)	1.02 (0.94 – 1.09)	1.00 (0.98 – 1.01)
<b>Localized prostate cancer<sup>4</sup> (No. of cases)</b>	141	673	857	536	434	2,500
Crude HR (95% CI) <sup>2</sup>	0.99 (0.82 – 1.19)	1.00 (ref)	1.06 (0.95 – 1.18)	1.00 (0.89 – 1.12)	0.99 (0.87 – 1.11)	0.98 (0.96 – 1.01)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.97 (0.81 – 1.17)	1.00 (ref)	1.07 (0.96 – 1.19)	1.02 (0.91 – 1.15)	1.02 (0.90 – 1.16)	0.99 (0.96 – 1.02)
<b>Advanced prostate cancer<sup>5</sup> (No. of cases)</b>	68	400	395	277	249	1,321
Crude HR (95% CI) <sup>2</sup>	1.14 (0.87 – 1.48)	1.00 (ref)	1.00 (0.87 – 1.16)	1.04 (0.89 – 1.21)	1.11 (0.95 – 1.31)	1.03 (1.00 – 1.06)
Multivariable adjusted HR (95% CI) <sup>3</sup>	1.16 (0.89 – 1.51)	1.00 (ref)	0.99 (0.85 – 1.14)	1.01 (0.86 – 1.19)	1.09 (0.92 – 1.29)	1.02 (0.99 – 1.06)
<b>Low-grade prostate cancer<sup>6</sup> (No. of cases)</b>	214	967	1119	766	691	3,543
Crude HR (95% CI) <sup>2</sup>	1.07 (0.92 – 1.24)	1.00 (ref)	1.05 (0.96 – 1.14)	1.00 (0.91 – 1.10)	1.05 (0.95 – 1.16)	0.99 (0.98 – 1.02)
Multivariable adjusted HR (95% CI) <sup>3</sup>	1.05 (0.90 – 1.23)	1.00 (ref)	1.06 (0.97 – 1.16)	1.02 (0.93 – 1.13)	1.09 (0.98 – 1.21)	1.01 (0.99 – 1.03)
<b>High-grade prostate cancer<sup>7</sup> (No. of cases)</b>	36	200	240	138	112	690
Crude HR (95% CI) <sup>2</sup>	0.99 (0.69 – 1.42)	1.00 (ref)	1.08 (0.89 – 1.31)	1.00 (0.80 – 1.25)	0.95 (0.75 – 1.20)	1.01 (0.96 – 1.05)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.99 (0.69 – 1.43)	1.00 (ref)	1.09 (0.90 – 1.33)	1.01 (0.81 – 1.27)	0.97 (0.76 – 1.25)	1.01 (0.97 – 1.06)
<b>Aggressive prostate cancer<sup>8</sup> (No. of cases)</b>	97	611	672	412	363	2,058
Crude HR (95% CI) <sup>2</sup>	0.97 (0.78 – 1.21)	1.00 (ref)	1.07 (0.95 – 1.19)	1.00 (0.88 – 1.13)	1.06 (0.93 – 1.21)	1.01 (0.99 – 1.03)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.98 (0.78 – 1.22)	1.00 (ref)	1.07 (0.95 – 1.20)	1.00 (0.88 – 1.14)	1.07 (0.93 – 1.23)	1.01 (0.99 – 1.04)
<b>Fatal prostate cancer (No. of cases)</b>	46	279	283	186	142	890
Crude HR (95% CI) <sup>2</sup>	1.01 (0.73 – 1.40)	1.00 (ref)	1.07 (0.90 – 1.27)	1.11 (0.92 – 1.33)	1.03 (0.83 – 1.26)	0.99 (0.95 – 1.03)
Multivariable adjusted HR (95% CI) <sup>3</sup>	1.02 (0.74 – 1.41)	1.00 (ref)	1.05 (0.88 – 1.25)	1.06 (0.88 – 1.29)	0.97 (0.79 – 1.21)	0.97 (0.93 – 1.01)

<sup>1</sup> Cut-off points are based on country-specific quartiles of total coffee intake after exclusion of non-consumers: Total cohort (136, 376, 654), Italy (60, 91, 131), Spain (49, 100, 161), UK (151,475, 502), The Netherlands (375, 625, 875), Greece (140, 170, 310), Germany (261, 428, 580), Sweden (321, 443, 610), Denmark (500, 900, 1300).

<sup>2</sup> Stratified by center, and age at recruitment in 5yr categories.

<sup>3</sup> Stratified by center, and age at recruitment in 5yr categories, and adjusted for smoking status, BMI, history of diabetes, alcohol intake, education, physical activity, energy intake, as well as calcium, fish, tea, fruit and vegetable intake.

<sup>4</sup> Tumor-node-metastasis staging score of T0-T2 and N0/NX and M0, or stage coded in the recruitment center as localized.

<sup>5</sup> T3-T4 and/or N1-N3 and/or M1, or stage coded in the recruitment center as metastatic.

<sup>6</sup> Gleason score of <8, or grade coded as well, moderately or poorly differentiated.

<sup>7</sup> Gleason score of ≥8, or grade coded as undifferentiated.

<sup>8</sup> High-grade or advanced disease or PSA>20 ng/mL at diagnosis

**Table 3 Hazard ratio (HR) and 95% confidence interval (CI) for the association between tea intake and risk of total prostate cancer and cancer by stage, grade and fatality**

	Thirds of observed tea intake <sup>1</sup>				
	Non consumer N= 50,140	1 (Low) N= 37,582	2 (Moderate) N= 32,185	3 (High) N= 21,289	Per 100 ml/L N= 91,056
<i>Median tea intake (ml /day)</i>	0	12	119	450	
<b>All prostate cancer (No. of cases)</b>	2,792	1,624	1,647	973	4,244
Crude HR (95% CI) <sup>2</sup>	0.91 (0.84 - 0.99)	1.00 (ref)	0.99 (0.92 - 1.06)	1.00 (0.92 - 1.09)	1.00 (0.99 - 1.01)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.93 (0.85 - 1.01)	1.00 (ref)	0.98 (0.91 - 1.05)	0.98 (0.90 - 1.07)	1.00 (0.99 - 1.01)
<b>Localized prostate cancer<sup>4</sup> (No. of cases)</b>	923	642	633	443	1,108
Crude HR (95% CI) <sup>2</sup>	0.85 (0.74 - 0.98)	1.00 (ref)	0.96 (0.86 - 1.07)	0.96 (0.85 - 1.09)	1.00 (0.98 - 1.01)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.87 (0.76 - 1.00)	1.00 (ref)	0.94 (0.84 - 1.06)	0.93 (0.82 - 1.06)	0.99 (0.98 - 1.01)
<b>Advanced prostate cancer<sup>5</sup> (No. of cases)</b>	443	364	373	209	946
Crude HR (95% CI) <sup>2</sup>	1.03 (0.87 - 1.21)	1.00 (ref)	0.92 (0.79 - 1.06)	0.97 (0.82 - 1.16)	0.99 (0.97 - 1.01)
Multivariable adjusted HR (95% CI) <sup>3</sup>	1.01 (0.86 - 1.20)	1.00 (ref)	0.94 (0.81 - 1.09)	1.01 (0.85 - 1.21)	1.00 (0.98 - 1.02)
<b>Low-grade prostate cancer<sup>6</sup> (No. of cases)</b>	1301	961	862	633	2,456
Crude HR (95% CI) <sup>2</sup>	0.86 (0.77 - 0.96)	1.00 (ref)	0.94 (0.86 - 1.04)	1.00 (0.90 - 1.10)	1.00 (0.99 - 1.01)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.88 (0.78 - 0.98)	1.00 (ref)	0.94 (0.85 - 1.03)	0.99 (0.89 - 1.10)	1.00 (0.98 - 1.01)
<b>High-grade prostate cancer<sup>7</sup> (No. of cases)</b>	211	192	210	113	515
Crude HR (95% CI) <sup>2</sup>	0.99 (0.77 - 1.28)	1.00 (ref)	1.10 (0.90 - 1.35)	1.07 (0.84 - 1.36)	0.98 (0.96 - 1.04)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.98 (0.76 - 1.27)	1.00 (ref)	1.11 (0.90 - 1.36)	1.09 (0.86 - 1.40)	1.01 (0.99 - 1.04)
<b>Aggressive prostate cancer<sup>8</sup> (No. of cases)</b>	687	539	609	320	1,468
Crude HR (95% CI) <sup>2</sup>	1.06 (0.92 - 1.23)	1.00 (ref)	1.07 (0.95 - 1.20)	1.04 (0.84 - 1.26)	1.00 (0.99 - 1.02)
Multivariable adjusted HR (95% CI) <sup>3</sup>	1.05 (0.91 - 1.22)	1.00 (ref)	1.08 (0.96 - 1.22)	1.06 (0.92 - 1.23)	1.00 (0.99 - 1.02)
<b>Fatal prostate cancer (No. of cases)</b>	348	239	239	110	588
Crude HR (95% CI) <sup>2</sup>	0.95 (0.75 - 1.20)	1.00 (ref)	0.99 (0.82 - 1.19)	0.92 (0.73 - 1.15)	0.99 (0.96 - 1.01)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.93 (0.74 - 1.18)	1.00 (ref)	0.97 (0.81 - 1.17)	0.89 (0.70 - 1.13)	0.98 (0.96 - 1.01)

<sup>1</sup> Cut-off points are based on country-specific tertiles of tea intake after exclusion of non-consumers: Total cohort (25, 281), Italy (10, 43), Spain (57, 171), UK (475, 855), The Netherlands (74, 238), Greece (0.5, 11), Germany (21, 145), Sweden (16, 179) and Denmark (16, 500).

<sup>2</sup> Stratified by center, and age at recruitment in 5yr categories.

<sup>3</sup> Stratified by center, and age at recruitment in 5yr categories, and adjusted for smoking status, BMI, history of diabetes, alcohol intake, education, physical activity, energy intake, as well as calcium, fish, coffee, fruit and vegetable intake.

<sup>4</sup> Tumor-node-metastasis staging score of T0-T2 and N0/NX and M0, or stage coded in the recruitment center as localized.

<sup>5</sup> T3-T4 and/or N1-N3 and/or M1, or stage coded in the recruitment center as metastatic.

<sup>6</sup> Gleason score of <8, or grade coded as well, moderately or poorly differentiated.<sup>7</sup> Gleason score of ≥8, or grade coded as undifferentiated.

<sup>8</sup> High-grade or advanced disease or PSA>20 ng/mL at diagnosis

**Table 4 Hazard ratio (HR) and 95% confidence interval (CI) for the association between caffeinated coffee intake and risk of total prostate cancer and cancer by stage, grade and fatality**

	Thirds of observed caffeinated coffee intake <sup>1</sup>				
	Non consumer N= 25,064	1 (Low) N= 31,350	2 (Moderate) N= 23,860	3 (High) N= 20,773	Per 100 ml/L N= 75,983
<i>Median caffeinated coffee intake (ml /day)</i>	0	81	475	787	
<b>All prostate cancer (No of cases)</b>	994	1,459	1,154	838	3,451
Crude HR (95% CI) <sup>2</sup>	0.96 (0.85 – 1.08)	1.00 (ref)	1.02 (0.94 – 1.10)	0.95 (0.87 – 1.04)	0.99 (0.98 – 1.00)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.97 (0.86 – 1.09)	1.00 (ref)	1.02 (0.94 – 1.10)	0.98 (0.89 – 1.07)	1.00 (0.99 – 1.01)
<b>Localized prostate cancer<sup>4</sup> (No of cases)</b>	529	423	311	257	991
Crude HR (95% CI) <sup>2</sup>	0.87 (0.72 – 1.06)	1.00 (ref)	1.00 (0.86 – 1.16)	1.00 (0.85 – 1.17)	0.99 (0.97 – 1.01)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.89 (0.73 – 1.08)	1.00 (ref)	1.01 (0.87 – 1.17)	1.03 (0.88 – 1.21)	1.00 (0.98 – 1.02)
<b>Advanced prostate cancer<sup>5</sup> (No of cases)</b>	146	258	196	135	589
Crude HR (95% CI) <sup>2</sup>	0.96 (0.73 – 1.25)	1.00 (ref)	0.98 (0.81 – 1.18)	0.97 (0.78 – 1.20)	1.00 (0.98 – 1.03)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.97 (0.74 – 1.28)	1.00 (ref)	0.98 (0.81 – 1.18)	0.96 (0.78 – 1.20)	1.00 (0.98 – 1.03)
<b>Low-grade prostate cancer<sup>6</sup> (No of cases)</b>	707	815	593	459	1,867
Crude HR (95% CI) <sup>2</sup>	0.93 (0.80 – 1.09)	1.00 (ref)	0.99 (0.89 – 1.10)	0.99 (0.88 – 1.18)	1.00 (0.99 – 1.02)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.94 (0.81 – 1.10)	1.00 (ref)	1.00 (0.90 – 1.12)	1.02 (0.91 – 1.15)	1.01 (0.99 – 1.02)
<b>High-grade prostate cancer<sup>7</sup> (No of cases)</b>	101	141	103	54	298
Crude HR (95% CI) <sup>2</sup>	0.75 (0.51 – 1.11)	1.00 (ref)	1.01 (0.78 – 1.30)	0.84 (0.61 – 1.15)	0.98 (0.94 – 1.02)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.75 (0.50 – 1.11)	1.00 (ref)	1.00 (0.77 – 1.30)	0.83 (0.60 – 1.15)	0.98 (0.94 – 1.02)
<b>Aggressive prostate cancer<sup>8</sup> (No of cases)</b>	279	394	296	190	880
Crude HR (95% CI) <sup>2</sup>	0.94 (0.75 – 1.17)	1.00 (ref)	1.00 (0.86 – 1.17)	0.96 (0.80 – 1.14)	1.00 (0.98 – 1.02)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.94 (0.75 – 1.18)	1.00 (ref)	1.01 (0.86 – 1.17)	0.96 (0.80 – 1.15)	1.00 (0.98 – 1.03)
<b>Fatal prostate cancer (No of cases)</b>	114	193	160	93	446
Crude HR (95% CI) <sup>2</sup>	0.93 (0.67 – 1.29)	1.00 (ref)	1.10 (0.89 – 1.36)	1.20 (0.93 – 1.55)	1.02 (0.99 – 1.05)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.97 (0.70 – 1.34)	1.00 (ref)	1.08 (0.87 – 1.34)	1.16 (0.89 – 1.51)	1.01 (0.98 – 1.04)

<sup>1</sup> Cut-off points are based on country-specific tertiles of caffeinated coffee intake after exclusion of non-consumers: Total cohort (150, 475), Italy (60, 104), Spain (2.0, 3.0), UK (190, 475), The Netherlands (360, 675), Greece (79, 170), Germany (290, 523), Sweden (343, 600).

<sup>2</sup> Stratified by center, and age at recruitment in 5yr categories.

<sup>3</sup> Stratified by center, age at recruitment in 5yr categories, and adjusted for smoking status, BMI, history of diabetes, alcohol intake, education, physical activity, energy intake, and calcium, fish, decaffeinated coffee, tea, fruit and vegetable.

<sup>4</sup> Tumor-node-metastasis staging score of T0-T2 and N0/NX and M0, or stage coded in the recruitment center as localized.

<sup>5</sup> T3-T4 and/or N1-N3 and/or M1, or stage coded in the recruitment center as metastatic.

<sup>6</sup> Gleason score of <8, or grade coded as well, moderately or poorly differentiated.<sup>7</sup> Gleason score of ≥8, or grade coded as undifferentiated.

<sup>8</sup> High-grade or advanced disease or PSA>20 ng/mL at diagnosis

**Table 5 Hazard ratio (HR) and 95% confidence interval (CI) for the association between decaffeinated coffee intake and risk of total prostate cancer and cancer by stage, grade and fatality**

	Thirds of observed decaffeinated coffee intake <sup>1</sup>				
	Non-consumer N= 57,655	1 (Low) N= 16,039	2 (Moderate) N= 6,636	3 (High) N= 10,453	Per 50 ml N= 33,128
<i>Median decaffeinated coffee intake (ml /day)</i>	0	2	75	190	
<b>All prostate cancer (No. of cases)</b>	2,145	521	200	388	1,109
Crude HR (95% CI) <sup>2</sup>	0.99 (0.87 – 1.13)	1.00 (ref)	0.91 (0.77 – 1.08)	0.99 (0.86 – 1.14)	1.00 (0.98 – 1.01)
Multivariable adjusted HR (95% CI) <sup>3</sup>	1.00 (0.87 – 1.14)	1.00 (ref)	0.92 (0.77 – 1.09)	1.00 (0.87 – 1.15)	1.00 (0.98 – 1.01)
<b>Localized prostate cancer<sup>4</sup> (No. of cases)</b>	1,034	120	59	130	309
Crude HR (95% CI) <sup>2</sup>	0.90 (0.73 – 1.11)	1.00 (ref)	0.66 (0.48 – 0.90)	0.91 (0.70 – 1.18)	1.02 (0.99 – 1.04)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.92 (0.75 – 1.13)	1.00 (ref)	0.67 (0.48 – 0.92)	0.93 (0.72 – 1.20)	1.02 (0.99 – 1.04)
<b>Advanced prostate cancer<sup>5</sup> (No. of cases)</b>	393	105	52	79	236
Crude HR (95% CI) <sup>2</sup>	0.88 (0.66 – 1.19)	1.00 (ref)	0.91 (0.64 – 1.29)	0.88 (0.64 – 1.20)	0.98 (0.95 – 1.02)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.88 (0.65 – 1.19)	1.00 (ref)	0.91 (0.64 – 1.29)	0.87 (0.64 – 1.19)	0.98 (0.95 – 1.02)
<b>Low-grade prostate cancer<sup>6</sup> (No. of cases)</b>	1,552	351	157	268	776
Crude HR (95% CI) <sup>2</sup>	1.02 (0.87 – 1.19)	1.00 (ref)	0.95 (0.77 – 1.15)	1.01 (0.85 – 1.19)	1.00 (0.98 – 1.02)
Multivariable adjusted HR (95% CI) <sup>3</sup>	1.03 (0.88 – 1.20)	1.00 (ref)	0.95 (0.78 – 1.16)	1.02 (0.86 – 1.21)	1.00 (0.98 – 1.02)
<b>High-grade prostate cancer<sup>7</sup> (No. of cases)</b>	222	77	15	51	143
Crude HR (95% CI) <sup>2</sup>	0.77 (0.53 – 1.11)	1.00 (ref)	0.52 (0.29 – 0.93)	0.84 (0.57 – 1.24)	1.01 (0.97 – 1.05)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.76 (0.52 – 1.11)	1.00 (ref)	0.52 (0.29 – 0.93)	0.83 (0.56 – 1.24)	1.00 (0.97 – 1.05)
<b>Aggressive prostate cancer<sup>8</sup> (No. of cases)</b>	609	186	75	133	394
Crude HR (95% CI) <sup>2</sup>	0.84 (0.67 – 1.06)	1.00 (ref)	0.92 (0.69 – 1.22)	0.91 (0.71 – 1.15)	0.99 (0.96 – 1.02)
Multivariable adjusted HR (95% CI) <sup>3</sup>	0.84 (0.67 – 1.06)	1.00 (ref)	0.92 (0.69 – 1.23)	0.90 (0.71 – 1.15)	0.99 (0.96 – 1.01)
<b>Fatal prostate cancer (No. of cases)</b>	242	79	24	45	148
Crude HR (95% CI) <sup>2</sup>	1.20 (0.80 – 1.81)	1.00 (ref)	1.08 (0.66 – 1.78)	0.83 (0.56 – 1.24)	0.95 (0.90 – 1.00)
Multivariable adjusted HR (95% CI) <sup>3</sup>	1.19 (0.79 – 1.80)	1.00 (ref)	1.07 (0.65 – 1.77)	0.85 (0.57 – 1.28)	0.95 (0.90 – 1.00)

<sup>1</sup> Cut-off points are based on country-specific tertiles of decaffeinated coffee intake after exclusion of non-consumers: Total cohort (2.2, 75), Italy (6.4, 20), Spain (2.0, 3.0), UK (2.0, 27), The Netherlands (63, 100) Greece (0.5, 11), Germany (19, 150).

<sup>2</sup> Stratified by center, and age at recruitment in 5 categories.

<sup>3</sup> Stratified by center, age at recruitment in 5 categories, and adjusted for smoking status, BMI, history of diabetes, alcohol intake, education, physical activity, energy intake, as well as calcium, fish, caffeinated coffee, tea, fruit and vegetable.

<sup>4</sup> Tumor-node-metastasis staging score of T0-T2 and N0/NX and M0, or stage coded in the recruitment center as localized.

<sup>5</sup> T3-T4 and/or N1-N3 and/or M1, or stage coded in the recruitment center as metastatic.

<sup>6</sup> Gleason score of <8, or grade coded as well, moderately or poorly differentiated.<sup>7</sup> Gleason score of ≥8, or grade coded as undifferentiated.

<sup>8</sup> High-grade or advanced disease or PSA>20 ng/mL at diagnosis.

**Table 6 Hazard ratio (HR) and 95% confidence interval (CI) for the association of continuous total coffee (200ml/day only among consumers) and tea (100ml/day only among consumers) consumption and prostate cancer risk by country and other baseline characteristics**

Country <sup>1</sup>	Total coffee intake		Tea intake	
	Cases/Control	HR (95% CI) <sup>2</sup>	Cases/Control	HR (95% CI) <sup>2</sup>
Denmark	1,832/ 23,776	0.99 (0.97 – 1.01)	1503/ 19015	1.00 (0.98 – 1.01)
Germany	796/ 19,386	0.98 (0.94 – 1.02)	619/ 15247	1.03 (1.00 – 1.06)
Greece	88/ 10,222	0.90 (0.65 – 1.25)	50/ 5850	1.14 (0.68 – 1.91)
Italy	479/13,553	0.89 (0.64 – 1.24)	254/ 7453	0.99 (0.87 – 1.14)
Spain	581/ 12,666	1.01 (0.85 – 1.20)	23/ 472	0.87 (0.63 – 1.22)
Sweden	1,767/ 19,769	0.99 (0.96 – 1.02)	616/ 10872	0.98 (0.93 – 1.02)
The Netherland	213/ 8,974	1.01 (0.93 – 1.09)	178/ 7870	1.01 (0.95 – 1.08)
UK	942/ 20,646	1.00 (0.96 – 1.04)	1001/ 21033	1.00 (0.98 – 1.02)
<b>P-heterogeneity, I<sup>2</sup></b>		0.98, 0.0%		0.61, 0.0%
<b>Baseline Age</b>				
< 60y	4,007/100,262	0.99 (0.97 – 1.01)	2582/ 69478	0.99 (0.98 – 1.01)
≥ 60y	2,660/ 28,664	1.01 (0.99 – 1.04)	1662/ 18334	1.01 (0.99 – 1.02)
<b>P-interaction</b>		<b>0.22</b>		<b>0.48</b>
<b>BMI</b>				
<30 Kg/m <sup>2</sup>	5,782/ 108,695	1.00 (0.98 – 1.01)	3767/ 76628	1.00 (0.99 – 1.01)
≥30 Kg/m <sup>2</sup>	885/ 19,673	1.00 (0.96 – 1.04)	477/ 11184	1.01 (0.98 – 1.05)
<b>P-interaction</b>		<b>0.70</b>		<b>0.50</b>
<25 Kg/m <sup>2</sup>	2,359/ 46,269	0.99 (0.97 – 1.01)	1603/ 35744	0.99 (0.98 – 1.01)
≥25 Kg/m <sup>2</sup>	4,308/ 82,099	1.00 (0.98 – 1.02)	2641/ 52068	1.00 (0.99 – 1.02)
<b>P-interaction</b>		<b>0.97</b>		<b>0.36</b>
<b>Smoking Status</b>				
Never Smoker	2,259/ 41,499	1.01 (0.98 – 1.04)	1551/ 32084	1.01 (0.99 – 1.02)
Ever smoker	4,353/ 85,121	0.99 (0.97 – 1.01)	2640/ 54267	1.00 (0.98 – 1.01)
<b>P-interaction</b>		<b>0.62</b>		<b>0.66</b>
<b>Physical Activity</b>				
Inactive	3,520/ 63,109	1.00 (0.98 – 1.03)	2166/ 41765	1.00 (0.99 – 1.02)
Active	3,054/ 62,463	0.99 (0.97 – 1.01)	1994/ 43524	1.00 (0.99 – 1.01)
<b>P-interaction</b>		<b>0.36</b>		<b>0.81</b>

<sup>1</sup> Coffee and tea information was missing for participants from Norway, France as well as n=1,828 participants from UK.

<sup>2</sup> From Cox proportional hazard models stratified by center and age at recruitment.